Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Bill Williams says BriaCell's engineered OTS cell lines express 15 HLA molecules across four lines. That lets them single-match over 99% of the population and double-match over 90%, making a personalized off-the-shelf therapy practical after only a one-week saliva test rather than complex tumor sequencing.

Related Insights

Most cell therapies target a single antigen on cancer cells. Luminary engineers its cells to recognize three different receptors. The therapy only needs one of the three to be present to work, making it significantly harder for cancer cells to mutate and "escape" the treatment.

Bill Williams says BriaCell further modified its OTS cells to express co-stimulatory molecules and cytokines. In lab studies, these OTS Plus cells activated naive T cells and killed cancer cells on repeated challenges, suggesting stronger and more durable immune activation than just HLA matching alone.

Bill Williams says HLA matching was not as critical for Bria-IMT when combined with an immune checkpoint inhibitor, so BriaCell is not matching patients for that product. The company is instead building HLA matching into its next-generation Bria-OTS and OTS Plus pipelines as those programs advance.

Many early cell therapies failed due to the impractical cost and complexity of individual manufacturing for each patient. Companies now succeeding are developing "off-the-shelf" treatments that don't require patient matching or immune suppression, creating a more scalable and commercially viable model similar to traditional drugs.

Unlike one-to-one autologous therapies, an allogeneic approach allows the creation of a master cell bank from a single donor. This bank can then reproduce enough cells to treat millions of patients, making it a truly off-the-shelf, scalable pharmaceutical.

Bill Williams says Bria-IMT presents many cancer-associated antigens, not just one, so it can activate adaptive T cells against multiple mutated tumor clones. He adds the cell-based approach also engages the innate immune system, which can recognize tumors undergoing immune evasion, further limiting cancer's ability to escape.

While personalized cancer vaccines require extracting and processing a patient's tumor, Create Medicines' in vivo approach is entirely off-the-shelf. By delivering the programming directly into the body, they enable the patient's own immune system to do the complex, personalized work of attacking the cancer itself.

Unlike many cell therapies, Rion's platelet-derived exosomes are devoid of the self/non-self surface markers that trigger immune rejection. This "immune privilege" is a critical biological advantage, allowing the product to be used as a universal, off-the-shelf therapy for any patient without needing donor matching.

Allogeneic ("off-the-shelf") CAR-T isn't just a cheaper alternative to autologous therapy; it's a medical necessity for certain cancers. In T-cell leukemia, the patient's own T-cells are cancerous and cannot be used to create a treatment. Therefore, therapy derived from a healthy donor is the only possible path forward for these patients.

The next wave of cell therapy, in vivo CAR-T, aims to turn the patient's body into the manufacturing plant. This eliminates the need for apheresis, external manufacturing, and lymphodepletion, effectively creating an off-the-shelf biologic that can be administered in community practices with no wait time.